pioglitazone has been researched along with Pituitary Neoplasms in 2 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Pituitary Neoplasms: Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In both pituitary and adrenocortical cancer, RGZ treatment results in inhibition of cell proliferation, through G0/G1 cell-cycle arrest and induction of cell apoptosis, leading to significant inhibition of tumor growth in the xenograft tumor models." | 2.46 | Role of the PPAR-γ system in normal and tumoral pituitary corticotropic cells and adrenal cells. ( Borgogni, E; Cantini, G; Canu, L; Ercolino, T; Luconi, M; Mangoni, M; Mannelli, M; Nesi, G; Piccini, V; Poli, G; Rapizzi, E, 2010) |
| "Pioglitazone was of similar potency to rosiglitazone in inhibiting proliferation." | 1.33 | PPAR-gamma expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-gamma receptor. ( Bonner, SE; Emery, MN; Galloway, M; Grossman, AB; Korbonits, M; Leontiou, C; Merulli, C; Musat, M; Nanzer, AM; Nikookam, K; Powell, M, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mannelli, M | 1 |
| Cantini, G | 1 |
| Poli, G | 1 |
| Mangoni, M | 1 |
| Nesi, G | 1 |
| Canu, L | 1 |
| Rapizzi, E | 1 |
| Borgogni, E | 1 |
| Ercolino, T | 1 |
| Piccini, V | 1 |
| Luconi, M | 1 |
| Emery, MN | 1 |
| Leontiou, C | 1 |
| Bonner, SE | 1 |
| Merulli, C | 1 |
| Nanzer, AM | 1 |
| Musat, M | 1 |
| Galloway, M | 1 |
| Powell, M | 1 |
| Nikookam, K | 1 |
| Korbonits, M | 1 |
| Grossman, AB | 1 |
1 review available for pioglitazone and Pituitary Neoplasms
| Article | Year |
|---|---|
Role of the PPAR-γ system in normal and tumoral pituitary corticotropic cells and adrenal cells.
Topics: Adrenal Cortex; Adrenal Cortex Neoplasms; Corticotrophs; Humans; Pioglitazone; Pituitary ACTH Hypers | 2010 |
1 other study available for pioglitazone and Pituitary Neoplasms
| Article | Year |
|---|---|
PPAR-gamma expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-gamma receptor.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Animals; Base Sequence; Case-Control Studies; Cell Line, Tu | 2006 |